Friday, 16 October 2026European Markets

BYGGMA Stock Bullish Momentum With A 10% Rise So Far Today

Loading stream...

(VIANEWS) - Shares of BYGGMA (Oslo Børs Benchmark Index_GI: BMA.OL) jumped by a staggering 10.98% to kr27.30 at 11:22 EST on Tuesday, after two consecutive sessions in a row of losses. Oslo Børs Benchmark Index_GI is rising 0.12% to kr1,218.16, after two successive sessions in a row of gains. This seems, up until now, a somewhat positive trend trading session today.

About BYGGMA

Byggma ASA manufactures and supplies building materials in Norway, Sweden, Denmark, Finland, the United Kingdom, the Netherlands, and internationally. It offers pre-painted ceilings and wall panels under the Huntonit brand name; I-beams for use in ceilings, walls, and floors in wood-based buildings under the brand name of Masonite; and particle boards, boards, and structural panels for use in buildings, interior ceilings, and wall panels under the Forestia brand name. The company also provides home lighting products under the Scan Lamps brand name; doors and windows for new buildings, extensions, and rehabilitation under the brand name of Uldal; a range of lamp and lighting products under the Aneta brand name; and develops, manufactures, and distributes MDF panels for walls, ceilings, bathrooms, and kitchens under the brand name of Smartpanel, as well as supplies OSB plywood and building boards under the brand name of Byggform. It exports its products. Byggma ASA is headquartered in Vennesla, Norway. Byggma ASA operates as a subsidiary of Investor As.

Earnings Per Share

As for profitability, BYGGMA has a trailing twelve months EPS of kr3.58.

PE Ratio

BYGGMA has a trailing twelve months price to earnings ratio of 7.63. Meaning, the purchaser of the share is investing kr7.63 for every norwegian krone of annual earnings.

Volatility

BYGGMA's last week, last month's, and last quarter's current intraday variation average was a positive 1.63%, a negative 0.32%, and a positive 1.75%.

BYGGMA's highest amplitude of average volatility was 1.63% (last week), 1.98% (last month), and 1.75% (last quarter).

More news about BYGGMA (BMA.OL).

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com